Related Experiment Videos
Myelofibrosis: a review of clinical and pathologic features and treatment
R E Smith1, M K Chelmowski, E J Szabo
1Department of Medicine, Medical College of Wisconsin, Milwaukee 53221.
Abstract:
The purpose of this review is to discuss and clarify the current understanding of the pathogenesis, clinical manifestations, and treatment of MF. MF may be either a primary or secondary disorder. It is characterized by an increased deposition of bone marrow collagen, fibronectin, and laminin. Present evidence indicates that MF may be mediated by platelet or megakaryocyte growth factors, decreased prostaglandin mediated stem cell inhibition, immune complex deposition, and both fibroblast and endothelial cell proliferation. Recently acute MF has been recognized to be identical to acute megakaryocytic leukemia. Secondary MF usually responds to appropriate treatment of the underlying disease. Primary MF is usually treated by blood product support, but may be responsive to androgens, splenectomy, splenic irradiation, chemotherapy, or bone marrow ablation with marrow reconstitution.
Insights
Myelofibrosis (MF) involves bone marrow collagen and fibronectin deposition. Treatment varies by type, with secondary MF responding to underlying disease management and primary MF requiring diverse interventions.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Myelofibrosis (MF) is a bone marrow disorder characterized by increased deposition of extracellular matrix components.
- MF can arise as a primary condition or secondary to other diseases.
- Pathogenic mechanisms involve growth factors, immune responses, and cellular proliferation.
Purpose of the Study:
- To review and clarify the current understanding of myelofibrosis.
- To discuss the pathogenesis, clinical features, and treatment options for MF.
Main Methods:
- This is a review article, synthesizing existing research and clinical knowledge.
- No new experimental data were generated.
Main Results:
- MF pathogenesis involves increased bone marrow collagen, fibronectin, and laminin.
- Potential mediators include growth factors, altered stem cell regulation, immune complexes, and cellular proliferation.
- Acute MF is now recognized as acute megakaryocytic leukemia.
Conclusions:
- Secondary MF treatment focuses on the underlying condition.
- Primary MF management includes blood support, androgens, splenectomy, irradiation, chemotherapy, or stem cell transplantation.